Psychosis in Later Life

Colijn, Mark A.; Nitta, Bradley H.; Grossberg, George T.

doi:10.1097/hrp.0000000000000068

Cited by 34 publications

(10 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who used TMZ combined with three or more parkinsonism-inducing drugs showed almost twice the risk of parkinsonism than those who used TMZ plus one of these drugs. This finding has particular significance for older patients subjected to polypharmacy, as they are more frequently prescribed parkinsonism-inducing medications, including antipsychotics, prokinetics, and CCBs, to treat multiple chronic conditions and decreased physiological functioning [ 27 , 28 ]. A study in older Korean patients found that, on average, more than three antipsychotic drugs were prescribed concurrently in psychiatric outpatient settings [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study

Kim

Kwon

et al. 2020

IJERPH

View full text Add to dashboard Cite

An association between trimetazidine (TMZ), an anti-anginal drug, and parkinsonism has been reported in a number of studies. However, evidence from studies with long-term follow-up and better validity is lacking. We investigated the risk of TMZ-associated parkinsonism, specifically the incidence rate, cumulative dose–response relationship, and combined effects with other parkinsonism-inducing medications. This propensity score-matched retrospective cohort study was conducted using 14-year health insurance claims data in South Korea. The risk of parkinsonism was evaluated using multivariate Cox proportional hazard regression analysis, adjusted for comorbidities and concurrent medications. A total of 9712 TMZ users and 29,116 matched non-TMZ users were included. TMZ users had a significantly higher incidence rate of parkinsonism than non-TMZ users (9.34 vs. 6.71 per 1000 person-years; p < 0.0001). TMZ use significantly increased the risk of parkinsonism (adjusted hazard ratio = 1.38; 95% confidence interval = 1.26–1.51). Increased risks were observed with accumulated doses of TMZ, as well as concurrent use of other parkinsonism-inducing medications. The findings indicate that TMZ use significantly increases the risk of parkinsonism in the South Korean population. Closer monitoring should be considered for TMZ users, especially for those who are older, using TMZ at high cumulative doses and other parkinsonism-inducing medications.

show abstract

Section: Discussionmentioning

confidence: 99%

Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study

Kim

Kwon

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Schizophrenia is the 15th leading cause of disability throughout the world (GDB 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017; National Institute of Mental Health [NIMH], 2018); it is a mental disorder that affects cognition, perception, language, behavior, and speech in more than 21 million individuals (American Psychiatric Association [APA], 2013; Colijn, Nitta, & Grossberg, 2015; Untu et al, 2015; World Health Organization, 2018). Until recently, a diagnosis of schizophrenia usually meant a lowered life expectancy (Al Jurdi, Rej, & Sajatovic, 2014; Almeida et al, 2014; Laursen, Nordentoft, & Mortensen, 2014; Mausbach & Ho, 2015; NIMH, 2018), with the hypothesis that older adults diagnosed with schizophrenia (OADWS) would die earlier than their peers who are not mentally ill, as a result of poor lifestyle choices, less access to health care, or poor compliance with treatments (Almeida et al, 2014; Cohen, Meesters, & Zhao, 2015).…”

Section: The Experience Of Schizophreniamentioning

confidence: 99%

“…In addition, some individuals experience late onset schizophrenia, usually at ages 40 to 60 years (Sachdev, Mohan, Taylor, & Jeste, 2015), or very late onset schizophrenia like psychosis, usually after 60 years (Sharma, Debsikdar, Naphade, & Shetty, 2014). Although individuals who receive a late or very late schizophrenia diagnosis do not fall within the classification of younger adult onset, they have complications associated with being OADWS, and they too are a concern for the health care system (Colijn et al, 2015; Pearman & Batra, 2012).…”

Section: The Experience Of Schizophreniamentioning

confidence: 99%

The Life Course Paradigm as a Lens for Holistic Nursing Research in Older Adults Diagnosed With Schizophrenia

Walker

2019

J Holist Nurs

View full text Add to dashboard Cite

Older adults diagnosed with schizophrenia (OADWS) have unique needs for care and live longer today than their forebears who were diagnosed with schizophrenia. As a result, nurses need to be prepared for the specific care of individuals who live with schizophrenia as they age. Together, Life Course Theory and holistic nursing suggest a good fit in the quest for successful solutions and/or outcomes for the unique problems that OADWS face. Holistic nursing views the patient as a whole person, considering all aspects of the patient’s experiences within life’s broader environment. The life course paradigm offers an effective way for nurses to understand issues that patients face throughout their lives, thus enhancing holistic nursing with a historical perspective. This is especially important for the care of OADWS, who face unique disparities as well as physical and psychological comorbidities over their life course. This article is intended to initiate a discussion of OADWS, focused with Life Course Theory as a holistic lens. Literature pertinent to the life course of OADWS is reviewed, followed by an analysis of the life course paradigm in relation to OADWS’ unique experiences. Conclusions support the holistic use of Life Course Theory in research and interventions for OADWS.

show abstract

“…The initial primary distinction to be made is between primary psychotic disorders and secondary psychotic disorders. 7…”

Section: Epidemiologymentioning

confidence: 99%

Psychotic disorders in late life: a narrative review

Tampi

Young

Hoq³

et al. 2019

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Psychotic disorders are not uncommon in late life. These disorders often have varied etiologies, different clinical presentations, and are associated with significant morbidity and mortality among the older adult population. Psychotic disorders in late life develop due to the complex interaction between various biological, psychological, social, and environmental factors. Given the significant morbidity and mortality associated with psychotic disorders in late life, a comprehensive work-up should be conducted when they are encountered. The assessment should not only identify the potential etiologies for the psychotic disorders, but also recognize factors that predicts possible outcomes for these disorders. Treatment approaches for psychotic disorders in late life should include a combination of nonpharmacological management strategies with the judicious use of psychotropic medications. When antipsychotic medications are necessary, they should be used cautiously with the goal of optimizing outcomes with regular monitoring of their efficacy and adverse effects.

show abstract

Psychosis in Later Life

Cited by 34 publications

References 147 publications

Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study

Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study

The Life Course Paradigm as a Lens for Holistic Nursing Research in Older Adults Diagnosed With Schizophrenia

Psychotic disorders in late life: a narrative review

Contact Info

Product

Resources

About